Lung Cancer: VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy
Peer reviewed journal: VeriStrat test identifies patients with squamous cell lung cancer who are more likely to have improved survival on afatanib (Gilotrif)
The GeneStrat test, a liquid biopsy test used in lung cancer, has earned approval from NY State-CLEP, along with several other demanding certifications.
The Positive Bioscience agreement will make GeneStrat and VeriStrat tests available in India
New Study Shows Advanced Diagnostic Tests, Including the VeriStrat® Test, Can Help Physicians Improve Cancer Care Planning and Reach Quality Measures For Patients
A new study demonstrates that VeriStrat can help physicians improve quality care and cancer care planning for patients with advanced lung cancer.
New Biodesix data on liquid biopsy genomic tests, evaluation of biological processes underlying mass spectrometry proteomic assays of human serum
New Data Show Biodesix’s VeriStrat® Test is Cost-Saving, Improves Survival and Quality of Life in Advanced Lung-Cancer Patients
VeriStrat test saved an average of $1,050 per patient while improving survival outcomes (as compared to patients treated without the use of the test).
Biodesix will present data from three studies at AACR 2017 annual meeting, on genomic and proteomic assays.
New Study Shows Biodesix’s VeriStrat Changes Treatment Decisions for Lung Cancer Patients; Reduces Over-Treatment at End of Life
A new study published in Current Medical Research and Opinion shows that VeriStrat changes treatment decisions for patients with lung cancer.
Dr. Jeffrey Weber will present study results of new Biodesix immunotherapy test at ITOC4
Biodesix and Progenetics have entered into an international agreement; Biodesix tests will be available in Israel for the first time.